REGN 1979

Drug Profile

REGN 1979

Alternative Names: REGN1979

Latest Information Update: 18 May 2016

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors; CD3 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute lymphoblastic leukaemia; B cell lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Dec 2015 Phase-I clinical trials in B-cell lymphoma in Spain (IV) (EudraCT2015-001697-17)
  • 01 Dec 2015 Phase-I clinical trials in B-cell lymphoma in Germany (IV)
  • 28 Jul 2015 Regeneron and Sanofi agree to co-develop and co-promote REGN 1979
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top